GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Owner Earnings per Share (TTM)

Surmodics (Surmodics) Owner Earnings per Share (TTM) : 0.11 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Surmodics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Surmodics's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.11. It's Price-to-Owner-Earnings ratio for today is 238.73.


The historical rank and industry rank for Surmodics's Owner Earnings per Share (TTM) or its related term are showing as below:

SRDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.76   Med: 43.96   Max: 1719.17
Current: 238.71


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Surmodics was 1719.17. The lowest was 17.76. And the median was 43.96.


SRDX's Price-to-Owner-Earnings is ranked worse than
92.88% of 281 companies
in the Medical Devices & Instruments industry
Industry Median: 32.43 vs SRDX: 238.71

Surmodics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.06. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38. It's PE Ratio ratio for today is 69.11.

Surmodics's EPS without NRI for the three months ended in Dec. 2023 was $-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.47. It's PE Ratio without NRI ratio for today is 55.75.


Surmodics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Surmodics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Owner Earnings per Share (TTM) Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 0.13 0.19 -2.20 -0.08

Surmodics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.50 -2.59 -0.37 -0.08 0.11

Competitive Comparison of Surmodics's Owner Earnings per Share (TTM)

For the Medical Devices subindustry, Surmodics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Surmodics's Price-to-Owner-Earnings falls into.



Surmodics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Surmodics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 5.5
Depreciation, Depletion and Amortization 8.7
Change In Deferred Tax -0.2
5Y Average of Maintenance Capital Expenditure 3.3
Change In Working Capital -9.3
Shares Outstanding (Diluted Average) 14.1

1. Start with "Net Income" from income statement. Surmodics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $5.5 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Surmodics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $8.7 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Surmodics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.2 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $3.3 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Surmodics's 5-Year Average Maintenance Capital Expenditure = $3.3 Mil

5. "Change In Working Capital" is from cashflow statement. Surmodics's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.3 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Surmodics's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 14.102 Mil.

Surmodics's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 5.521 +8.733+-0.171
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-3.2629221276208+-9.275)/14.102
=0.11

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=26.26/0.11
=238.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Surmodics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Surmodics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines

From GuruFocus